ASTS
AST SpaceMobile, Inc.
ASTS has slightly lower modeled downside risk, despite its lower overall score.
ICHR
Ichor Holdings, Ltd.
ICHR has the edge over ASTS overall on the model score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ICHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
ICHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
ICHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $37.07 | — |
| Cheap | 13x | $0.63 | -98% |
| Fair | 20x | $1.01 | -97% |
| Expensive | 42x | $2.11 | -94% |
| Current | 741x | $37.07 | — |
Historical ranges are pointers, not guarantees.
ICHR's PE is in its expensive range at 741x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
ICHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for ICHR, with profitability improving.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
ICHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.14 | +6172% |
| Q3 2026 | $0.05 | +$1.24 |
| Q2 2026 | -$1.17 | -$0.57 |
| Q1 2026 | -$1.48 | -$1.01 |
| Q4 2025 | -$1.54 | -$0.90 |
| Q3 2025 | -$1.19 | -$0.26 |
| Q2 2025 | -$0.60 | +$0.61 |
| Q1 2025 | -$0.47 | +$1.30 |
| Q4 2024 | -$0.64 | +$0.83 |
ICHR has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over ICHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
ICHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328.7M | +37% |
| Q2 2026 | $294.8M | +23% |
| Q1 2026 | $256.1M | +4.7% |
| Q4 2025 | $223.6M | -4.2% |
| Q3 2025 | $239.3M | +13% |
| Q2 2025 | $240.3M | +18% |
| Q1 2025 | $244.5M | +21% |
| Q4 2024 | $233.3M | +15% |
ICHR's revenue is growing: $329M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.9% | +15 points |
| Q2 2026 | 2.4% | +4.4 points |
| Q1 2026 | 0.8% | +1.3 points |
| Q4 2025 | -6.2% | -5.7 points |
| Q3 2025 | -8.1% | -7.9 points |
| Q2 2025 | -2% | -0.9 points |
| Q1 2025 | -0.5% | +1.4 points |
| Q4 2024 | -0.5% | +3.4 points |
ICHR has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
ICHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -1983% |
| Q2 2026 | -$23.6M | -$8.8M |
| Q1 2026 | -$10M | -2113% |
| Q4 2025 | $5.9M | +$12.8M |
| Q3 2025 | $2.1M | -3.3% |
| Q2 2025 | -$14.8M | -201% |
| Q1 2025 | $496K | +58% |
| Q4 2024 | -$6.9M | -119% |
ICHR has the edge over ASTS on cash flow, with more consistent year-over-year improvement.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over ICHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
ICHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.9M shares |
| 1 year | +11% | +3.8M shares |
| 3 years | +30% | +8.9M shares |
| 5 years | +31% | +9.1M shares |
| Available history | +67% | +15.4M shares |
ICHR has 38M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ICHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -16.3x | Net Cash |
| Q3 2025 | 6.5x | High |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.9x | Very low |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 1.1x | Healthy |
ICHR has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
ICHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 10.0 | Oversold |
ICHR's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
ICHR PE vs Technology Sector
| Metric | ICHR | Sector median | Relative |
|---|---|---|---|
| PE | 741x | 28x | 2,561% above |
| PE % | 100 | 35 | 65 pts above |
ICHR is trading at 741x earnings, a 2561% premium to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
ICHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 19% below |
| 20 week MA | $61.7 | 40% below |
| 50 week MA | $54.6 | 32% below |
| 100 week MA | $38.3 | 3.1% below |
| 200 week MA | $35.8 | 3.5% above |
ICHR has fallen below most of its moving averages, though it's still 3.5% above its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
ICHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $30.5 | -10% |
| 2021 | $30.5 | $45.5 | +49% |
| 2022 | $45.5 | $26.2 | -42% |
| 2023 | $26.2 | $33.6 | +28% |
| 2024 | $33.6 | $31.4 | -6.7% |
| 2025 | $31.4 | $19.0 | -40% |
| 2026 YTD | $19.0 | $37.1 | +96% |
ICHR has the edge over ASTS on returns for 2026, with the stronger performance.